Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $47.29
    -3.73 (-7.31%)

    Market Cap: $1.53B

    Last updated: Nov 17, 2026 at 4:32 PM ET

    GeneDx Holdings Corp. (WGS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    GeneDx Holdings (WGS) has a market cap of $1.53B and an enterprise value of $1.64B. It kept -24.10% of revenue as net income over the last 12 months. Its share count is up 3.76% from a year earlier.

    Total Valuation

    Enterprise value is 7.42% above the market cap, as debt exceeds cash.

    Market Cap$1.53B
    Enterprise Value$1.64B
    Latest price (Nov 17, 2026)$47.29

    Key Dates

    The next earnings report is set for Feb 22, 2027, after the close.

    Next Earnings DateFeb 22, 2027, after the close
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.57% in the quarter ended Sep 30, 2026 and grew 5.01% a year over 2 years.

    Shares Outstanding29.88M
    Shares Change (YoY)+3.76%
    Shares Change (QoQ)+0.57%
    Share Count Growth (2Y CAGR)+5.01%

    Valuation Ratios

    Sales and book value multiples are 3.1x and 5.8x.

    P/E Ratio315.3x
    Forward P/E468.2x
    P/S Ratio3.1x
    Forward P/S3.2x
    P/B Ratio5.8x
    P/TBV Ratio13.4x
    PEG Ratio8.3

    Valuation history and multiples

    Price Statistics

    The stock is down 63.07% over 52 weeks and trades 34.65% below its 50-day average.

    Beta (1Y)1.63
    52-Week Change-63.07%
    1-Month Change-28.66%
    3-Month Change-40.63%
    6-Month Change+12.25%
    5-Year Change-74.07%
    Total Return (1Y)-63.07%
    Total Return (3Y CAGR)+209.10%
    Total Return (5Y CAGR)-27.32%
    Return vs SPY (1Y)-74.30%
    Max Drawdown (1Y)-79.40%
    Max Drawdown (3Y)-79.40%
    Sharpe Ratio (1Y)-0.97
    Correlation with SPY (1Y)0.22
    50-Day Average$72.36
    200-Day Average$69.41
    52-Week Range$32.21 to $170.87
    RSI (14 Days)32.0
    Average Volume (20 Days)1.20M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.16x current liabilities, and total debt is 0.86x shareholder equity.

    Current Ratio4.16x
    Quick Ratio3.85x
    Debt / Equity0.86x

    Returns and Efficiency

    Return on invested capital is -22.08% over the last 12 months, against a 5-year average of -4.48%.

    Return on Equity (ROE)-45.38%
    Return on Assets (ROA)-21.09%
    Return on Invested Capital (ROIC)-22.08%
    Return on Capital Employed (ROCE)-22.07%
    ROE (5Y Average)-76.97%
    ROA (5Y Average)-42.91%
    ROIC (5Y Average)-4.48%
    Asset Turnover0.90x
    Inventory Turnover7.29x
    Receivables Turnover5.24x
    Cash Conversion Cycle25 days

    Scores

    WGS has an Altman Z-Score of -0.13, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.13
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $460.78M over the last 12 months is up 14.57% from the 12 months before.

    Revenue$460.78M
    Revenue Growth (YoY)+14.57%
    Gross Profit$316.78M
    Operating Income-$99.59M
    Pretax Income-$111.21M
    Net Income-$111.05M
    EBITDA-$73.14M
    EBIT-$100.44M
    Reported EPS (TTM)$0.15

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 46.48% of the $526.48M in total assets.

    Cash and Equivalents$96.14M
    Total Debt$209.56M
    Net Debt$113.42M
    Net Debt Per Share$3.80
    Working Capital$225.49M
    Shareholder Equity$244.69M
    Book Value Per Share$8.19
    Tangible Book Value$105.32M
    Tangible Book Per Share$3.52
    Total Assets$526.48M
    Total Liabilities$281.80M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $26.14M of capital spending, operating cash flow left -$101.22M of free cash flow.

    Operating Cash Flow-$75.08M
    Capital Expenditures$26.14M
    Free Cash Flow-$101.22M
    FCF Per Share-$3.39
    Depreciation and Amortization$27.30M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -21.61%.

    Gross Margin68.75%
    Operating Margin-21.61%
    Pretax Margin-24.13%
    Net Margin-24.10%
    EBITDA Margin-15.87%
    EBIT Margin-21.80%
    FCF Margin-21.97%
    Gross Margin (5Y Average)31.72%
    Net Margin (5Y Average)-91.67%

    Growth

    Revenue grew 22.13% a year over 3 years.

    Revenue Growth (3Y CAGR)+22.13%
    Revenue Growth (5Y CAGR)+18.98%
    Book Value Per Share Growth (2Y CAGR)+14.27%
    Tangible Book Per Share Growth (2Y CAGR)+48.35%

    Revenue and profit by year

    Dividends and Yields

    WGS does not pay a dividend. Its free cash flow yield is -7.16%.

    Earnings Yield0.32%
    FCF Yield-7.16%
    Buyback Yield-2.13%
    Shareholder Yield-2.13%

    Stock Splits

    The last split was a 1-for-33 reverse split on May 4, 2023.

    Last Split DateMay 4, 2023
    Split TypeReverse split
    Split Ratio1:33

    Analyst Forecast

    Consensus estimates put revenue growth at 15.43% and EPS growth at -5.26% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+15.43%
    EPS Growth Forecast (2Y CAGR)-5.26%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About WGS

    What is WGS's market cap?

    GeneDx Holdings has a market cap of $1.53B. Its enterprise value, which adds debt and subtracts cash, is $1.64B.

    What is WGS's P/E ratio?

    GeneDx Holdings has a trailing P/E ratio of 315.3x and a forward P/E of 468.2x.

    How many shares of WGS are outstanding?

    GeneDx Holdings has 29.88M shares outstanding. The count is up 3.76% from a year earlier.

    Does WGS pay a dividend?

    No. GeneDx Holdings does not pay a dividend.

    How much debt does WGS have?

    GeneDx Holdings has $209.56M of total debt and $96.14M of cash and equivalents, a net debt position of $113.42M.